Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy

  • RISK GROUPS AND CLINICAL SUBTYPES TO PROGNOSTICATE MCRPC
  • Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, Lance Leopold, Matthew D. Galsky, Guru Sonpavde
  • BJU International, April 2012, Wiley
  • DOI: 10.1111/j.1464-410x.2012.11148.x

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1111/j.1464-410x.2012.11148.x

In partnership with:

Link to Wiley showcase